Format

Send to

Choose Destination
Curr Opin Immunol. 2017 Dec;49:56-63. doi: 10.1016/j.coi.2017.09.006. Epub 2017 Oct 17.

Biomarker-guided stratification of autoimmune patients for biologic therapy.

Author information

1
Department of Surgery, University of British Columbia, Canada; BC Children's Hospital Research Institute, Canada.
2
Université de Montréal, Canada; Institut de Cardiologie de Montréal, Canada.
3
Université de Montréal, Canada; Hôpital Maisonneuve Rosemont, Canada.
4
Department of Surgery, University of British Columbia, Canada; BC Children's Hospital Research Institute, Canada. Electronic address: mlevings@bcchr.ca.

Abstract

Autoimmunity results from an intersection of genetic and environmental factors that cause patient-specific perturbations in immune homeostasis. Defining autoimmunity-associated genetic factors has led to mechanistic insight into underlying etiologies, and the development of many biologic therapies that target the immune system. However, biomarker-informed pairing of patients with optimal biologic therapy is lacking. Here, we discuss platforms commonly used to find biomarkers that predict response to biologic therapy in autoimmunity and highlight recent biomarker discoveries. We also outline how the lack of assay standardization is a barrier to successful biomarker validation. Finally, we argue that the successful development of companion biomarkers for biologic therapy requires collaborative approaches that integrate multiple platforms and enable comprehensive measurement of multiple immune pathways.

PMID:
29053992
DOI:
10.1016/j.coi.2017.09.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center